John Murphy, M.D., MPH, DPH, President COVID-19 Long-haul Foundation
Abstract
Persistent, debilitating fatigue and exertional intolerance are among the most frequent and disabling features of post-acute sequelae of SARS-CoV-2 infection (PASC, “long-COVID”). Accumulating evidence implicates multi-level bioenergetic dysfunction — from altered systemic metabolism and metabolomics profiles to impaired mitochondrial respiration in immune and other peripheral cells — as a core contributor to the symptom cluster commonly labelled “exhaustion.” This article synthesizes current evidence for mechanisms linking SARS-CoV-2 infection to sustained energy depletion, integrates findings from long-COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) literature, and outlines diagnostic approaches, clinical features, and therapeutic implications. We review viral persistence, autoimmunity, endothelial and microvascular pathology, immune-mediated metabolic reprogramming, mitochondrial damage, redox imbalance, and their intersections with neuroinflammation and autonomic dysfunction. We emphasize heterogeneity across patient subgroups and the need for standardized bioenergetic assays and multi-omic phenotyping to advance diagnostics and therapeutics. Nature+2PMC+2
Keywords
Long-COVID; PASC; fatigue; mitochondrial dysfunction; energy metabolism; immunometabolism; myalgic encephalomyelitis; post-infectious fatigue. Nature
1. Introduction
SARS-CoV-2 infection has produced a substantial global burden of persistent symptoms in a subset of survivors, collectively termed long-COVID or PASC. Fatigue, post-exertional malaise (PEM), cognitive dysfunction (“brain fog”), orthostatic intolerance and exercise intolerance are among the most frequently reported complaints, often lasting months to years and impairing quality of life. Epidemiologic and mechanistic work suggests several overlapping pathophysiologic pathways, with energy metabolism emerging as a central axis linking immune activation, endothelial dysfunction, and neuronal symptoms. Recent comprehensive reviews and multi-omic studies have highlighted mitochondrial and metabolic signatures in long-COVID cohorts. Nature+2PMC+2
2. Epidemiology and clinical scope of exhaustion in long-COVID
Large cohorts and systematic characterizations show that a notable minority of SARS-CoV-2 infected individuals develop prolonged fatigue and related syndromes. Estimates vary by case definition, cohort, variant era and vaccination status. Several reports suggest that between ~5–15% of infected individuals experience persistent symptoms at months post infection in many cohorts, with fatigue among the top complaints (exact prevalence varies). Long-COVID is heterogeneous; symptom clusters have been identified (e.g., cardiopulmonary, neurocognitive, musculoskeletal) and fatigue often co-occurs with cognitive symptoms and autonomic complaints. The Guardian+2TIME+2
Clinical phenotype of exhaustion: The core features relevant to energy depletion are: (1) persistent, disproportionate physical and mental fatigue; (2) post-exertional symptom exacerbation (PEM) with delayed recovery; (3) reduced exercise tolerance and rapid fatigability; (4) cognitive complaints and sleep disturbance; (5) orthostatic intolerance in many patients. These phenotypes overlap substantially with ME/CFS and other post-infectious fatigue states. Cell+1
3. Proposed etiologies linking SARS-CoV-2 to sustained energy depletion
Multiple, non-mutually exclusive mechanisms are proposed. Evidence supports contributions from (A) persistent viral antigens or low-level replication; (B) sustained immune activation and cytokine signaling; (C) autoantibodies and post-infectious autoimmunity; (D) endothelial and microvascular dysfunction including microthrombi; (E) direct mitochondrial perturbation and altered cellular metabolism; and (F) neuroimmune and autonomic dysregulation. These mechanisms interact to produce an energy crisis at the cellular and systemic level. PMC+2Nature+2
3.1 Viral persistence and antigen reservoirs
Several studies detect viral RNA, proteins, or antigenic fragments persisting in tissues (gut, lymphoid tissue, olfactory mucosa) months after acute infection in subsets of patients; persistent antigenic stimulation could sustain local and systemic inflammation and metabolic rewiring. While direct causal proof linking tissue persistence to fatigue is incomplete, the concept of antigen persistence as a driver of chronic immune activation and metabolic consequences is plausible and supported by immunologic profiling studies. PMC+1
3.2 Chronic immune activation and cytokine signaling
Protracted cytokine and interferon signaling (for example, persistently elevated IFN-γ in some cohorts) has been reported and associates with fatigue and muscle symptoms in selected studies. Chronic cytokine exposure can induce metabolic shifts (Warburg-like glycolytic shift in immune cells), reduce mitochondrial oxidative phosphorylation capacity, and increase reactive oxygen species (ROS), all contributing to decreased efficiency of ATP generation. Financial Times+1
3.3 Autoimmunity and pathogenic autoantibodies
Autoantibodies directed at neural or autonomic targets, G-protein coupled receptors, or endothelial components have been reported in both ME/CFS and long-COVID cohorts; these may produce dysautonomia, microvascular dysfunction, and altered perfusion to muscles and brain, thereby reducing oxygen delivery and exacerbating energetic deficits. The autoimmunity hypothesis remains under investigation and may explain a subset of patients. Cell+1
3.4 Endothelial, microvascular and coagulation abnormalities
Endothelial activation, microclots, and microvascular dysregulation have been proposed as contributors to tissue hypoperfusion and impaired oxygen delivery in long-COVID. Microvascular dysfunction can amplify energetic stress by limiting oxygen and substrate delivery necessary for mitochondrial ATP production. Nature+1
3.5 Direct mitochondrial insults and metabolic reprogramming
SARS-CoV-2 viral proteins interact with host mitochondrial pathways in vitro, and multiple clinical studies report signatures consistent with mitochondrial dysfunction in PBMCs and plasma metabolomics in long-COVID patients (impaired oxidative phosphorylation, altered lipid metabolism, reduced glutathione, altered amino acid metabolites). These data suggest that mitochondrial impairment—whether from direct viral interaction, immune-mediated damage, oxidative stress, or mitochondrial-nuclear communication failure—plays a central role in energy depletion. PMC+2ScienceDirect+2
4. Cellular and systems-level physiology of energy depletion
4.1 Mitochondrial bioenergetics: basic principles
Mitochondria generate ATP via oxidative phosphorylation (OXPHOS) coupling substrate oxidation to a proton gradient and ATP synthase activity. The balance between OXPHOS and glycolysis, mitochondrial membrane potential (ΔΨm), reactive oxygen species (ROS) generation, and mitochondrial dynamics (fusion/fission, mitophagy) determine cellular energy competence. Disruption at any of these nodes can manifest as reduced ATP availability, early fatigue with exertion, and impaired recovery. ScienceDirect
4.2 Immunometabolism and the metabolic cost of immune activation
Activated immune cells reprogram metabolism (e.g., increased glycolysis, reduced spare respiratory capacity in mitochondria) to support effector functions. Chronic, low-grade immune activation — as documented in subsets of long-COVID patients — can divert systemic energy substrates, increase resting metabolic demands, and reduce physiological reserve for muscular or cognitive tasks, producing subjective and objective fatigue. OUP Academic+1
4.3 Oxidative stress and antioxidant depletion
Sustained inflammation produces ROS and reactive nitrogen species; chronic oxidative stress damages mitochondrial DNA, lipids, and proteins, impairing electron transport chain function. Several studies show altered antioxidant status (e.g., glutathione) in PASC cohorts, suggesting oxidative injury as a mediator of mitochondrial impairment. Frontiers+1
4.4 Vascular and autonomic contributions to impaired energy delivery
Autonomic dysfunction (orthostatic intolerance, postural tachycardia) and endothelial abnormalities can reduce perfusion to skeletal muscle and brain during activity, producing mismatch between energy demand and oxygen/substrate supply; this mismatch manifests clinically as rapid fatigability and PEM. Microvascular dysfunction also impairs substrate exchange even when global metrics (blood pressure) are normal. Nature
5. Pathology and tissue-level observations
5.1 Blood and immune cell findings
Assays of peripheral blood mononuclear cells (PBMCs) from long-COVID patients show reduced mitochondrial respiration, lower maximal respiratory capacity, and altered coupling efficiency in several cohorts. Proteomic and metabolomic plasma studies reveal signatures of impaired fatty-acid oxidation, altered amino-acid metabolism, and markers consistent with oxidative stress. These peripheral signatures can correlate with symptom severity in some studies. ScienceDirect+2PMC+2
5.2 Muscle and exercise physiology
Exercise testing in subsets of patients reveals reduced peak VO₂, early anaerobic threshold, and abnormal recovery kinetics, often reflecting impaired peripheral oxygen utilization rather than isolated deconditioning in many cases. Muscle biopsies remain limited but have shown mitochondrial abnormalities in some post-infectious fatigue syndromes; more systematic muscle histology in long-COVID is needed. The Lancet+1
5.3 Central nervous system and neuroinflammatory findings
Neuroimaging studies in COVID survivors indicate changes in gray matter volume and functional connectivity in some cohorts, and neuroinflammation is proposed as a mechanism for cognitive fatigue. Neuroimmune activation can alter cerebral energy metabolism and neurotransmitter pathways, compounding peripheral energy deficits. Le Monde.fr+1
6. Clinical diagnostic parameters and biomarkers
No single diagnostic biomarker for long-COVID fatigue is validated. However, a multi-modal approach improves characterization:
- Clinical phenotype and validated questionnaires: e.g., Fatigue Severity Scale (FSS), Chalder Fatigue Scale, DePaul Symptom Questionnaire for PEM — central to diagnostic ascertainment and grading severity.
- Functional testing: 6-minute walk test, cardiopulmonary exercise testing (CPET) including two-day CPET to assess PEM and recovery kinetics. Abnormal CPET profiles (reduced peak VO₂; early rise in ventilatory equivalents) have been reported in long-COVID cohorts.
- Laboratory and multi-omic assays: targeted metabolomics (acylcarnitines, fatty acids, amino acids), plasma proteomics, cytokine panels (e.g., IFN-γ), and assays of oxidative stress (GSH/GSSG). PBMC mitochondrial respiration (Seahorse assay) and mitochondrial membrane potential measurements have shown group differences in several studies and are promising translational assays.
- Autonomic testing: tilt table testing, active stand tests; heart-rate variability metrics.
- Neuroimaging: where cognitive deficits predominate, MRI, PET and functional imaging may reveal changes consistent with neuroinflammation or altered perfusion. ScienceDirect+2MedRxiv+2
Post Type: “Post”
Key load-bearing findings (supported across multiple cohorts): PBMC mitochondrial respiratory deficits, plasma metabolomic signatures of impaired fatty-acid oxidation and altered amino-acid profiles, and persistent immunologic signatures in some patients (e.g., elevated IFN-γ). ScienceDirect+2PMC+2
7. Differential diagnosis: ME/CFS and other post-infectious syndromes
There is substantial phenotypic and mechanistic overlap between long-COVID fatigue and ME/CFS, including PEM, cognitive dysfunction, autonomic symptoms, and evidence of mitochondrial/energetic abnormality in many studies. Lessons from ME/CFS research (heterogeneity, need for standardized outcome measures, multi-omic phenotyping) apply directly to long-COVID. However, long-COVID cohorts also present unique immunologic and vascular features linked to the specific biology of SARS-CoV-2. Comparative studies are essential to delineate shared vs disease-specific mechanisms. Science+1
8. Therapeutic implications and interventions
No approved disease-modifying therapy specifically targets long-COVID fatigue; approaches are currently symptomatic, rehabilitative, or investigational. Therapeutic strategies under study or proposed include:
- Metabolic modulators / mitochondrial support: Compounds aiming to improve mitochondrial function or substrate utilization (nutraceuticals like coenzyme Q10, L-carnitine; investigational metabolic modulators such as AXA1125) have been explored with mixed evidence; mechanistic rationale exists, but high-quality RCT data are limited. European Society of Medicine -+1
- Anti-inflammatory / immunomodulatory therapies: For patients with clear immune-mediated signatures or autoantibodies, targeted immunomodulation (monoclonal antibodies, small molecules) is being investigated, though evidence is preliminary. Nature
- Antiviral / antigen-targeting strategies: If viral persistence is demonstrated, antiviral approaches could be rational; clinical trials are required. PMC
- Rehabilitation and pacing: Tailored physical rehabilitation, energy-conservation strategies (pacing) and graded programs may benefit some patients; caution is advised in PEM-predominant patients where overexertion can worsen symptoms. Evidence is mixed and individualized planning is essential. Verywell Health
- Autonomic and vascular interventions: Treatments for orthostatic intolerance (volume expansion, salt, compression garments, medications) and therapies targeting endothelial function are symptomatic options with rationale in subsets. Nature
Overall, the heterogeneity of mechanisms suggests precision medicine approaches guided by biomarker subtyping will be required to identify effective interventions. The Lancet
9. Research gaps and priorities
To progress from description to mechanism-driven therapy, key priorities include:
- Standardized phenotyping: harmonized clinical definitions, PEM assessment, CPET protocols (including two-day CPET) and autonomic testing. Cell
- Longitudinal, multi-omic cohorts: integration of proteomics, metabolomics, transcriptomics, immunophenotyping and mitochondrial functional assays to identify stable biomarker clusters and causative pathways. PMC+1
- Tissue studies: targeted biopsies and tissue studies (e.g., muscle, gut) to localize mitochondrial pathology and antigen persistence. PMC
- Mechanistic interventional trials: small, mechanism-guided RCTs (e.g., antioxidant/mitochondrial rescue, immunomodulation in autoantibody-positive subgroups, antivirals where persistence is found). Frontiers+1
- Cross-disease comparison: direct comparative studies with ME/CFS and other post-infectious fatigue states to identify shared and unique biology. Science
10. Conclusions
Energy depletion in long-COVID appears to be a multi-factorial syndrome arising from the interplay of persistent immune activation, autoimmunity, endothelial and microvascular dysfunction, and direct or indirect mitochondrial impairment. Peripheral signals — including PBMC respiratory deficits and plasma metabolomic changes — provide convergent evidence for impaired oxidative metabolism in many patients. The heterogeneity of findings mandates a precision approach that combines robust clinical phenotyping with multi-omic and functional bioenergetic assays to stratify patients and guide targeted interventions. A research agenda prioritizing longitudinal cohorts, mechanistic trials, and harmonized testing will be essential to translate mechanistic insights into effective treatments for exhaustion in long-COVID. ScienceDirect+2Nature+2
Selected references
Because this manuscript synthesizes many contemporary studies, below I list the most salient, recent peer-reviewed works and reviews cited in the text. For submission, I can convert these into any required journal format (e.g., Nature, Science) and expand the reference list to include 25+ full primary studies and reviews (I already used 25+ sources in composing the manuscript and can present them formatted with DOIs).
- Molnar T, et al. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. GeroScience. 2024. PMC
- Ward C, et al. Post-Acute Sequelae and Mitochondrial Aberration in SARS-CoV-2. 2024. PMC
- Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023. Nature
- Madsen HB, et al. Mitochondrial dysfunction in acute and post-acute phases of COVID-19. 2024. Nature
- Dirajlal-Fargo S, et al. Altered mitochondrial respiration in PBMCs of post-acute sequelae of SARS-CoV-2 infection. 2024. ScienceDirect
- Wei Y, et al. Proteomic and metabolomic profiling uncovers signatures in long COVID plasma. 2024. PMC
- López-Hernández Y, et al. The plasma metabolome of long COVID patients two years after infection. medRxiv. 2023. MedRxiv
- Gu X, et al. Probing long COVID through a proteomic lens. EBioMedicine. 2023. The Lancet
- Komaroff AL. Causes of symptoms and symptom persistence in long COVID. Cell Reports Medicine. 2025. Cell
- Syed AM, et al. Mitochondrial Dysfunction in ME/CFS. Physiol Rev / Transl Med. 2025. PMC+1
- Díaz-Resendiz KJG, et al. Loss of mitochondrial membrane potential in leucocytes as post-COVID sequelae. J Leukoc Biol. 2022. (cited in Davis 2023). Nature
- Maison DP, et al. Peripheral immune progression to long COVID. 2025. ScienceDirect
- Gu X et al. Proteomic longitudinal study. 2023. The Lancet
- National Academies. Chapter: Postacute Sequelae of SARS-CoV-2 Infection. 2024 workshop report. National Academies
- Taenzer M, et al. Urine metabolite analysis to identify pathomechanisms of LC and ME/CFS. 2023. PMC
- Molnar T. Mitochondrial dysfunction review. 2024. PMC
- Russell M, et al. Insights into long COVID fatigue biology and AXA1125. 2024. European Society of Medicine –
- Nature Immunology study (2025) — immunologic and proteomic profiling of long-COVID cohorts. Nature
- Lancet/EBioMedicine proteomic analyses. The Lancet
- Frontiers in Immunology / Translational studies on mitochondrial metabolic rescue. Frontiers+1
- IFM clinical overview on mitochondrial impairment. IFM
- Mitochondrial comparisons across aging, HIV, and long-COVID. MDPI 2025. MDPI
- Wellcome Open Research / protocols for metabolomics in long COVID. Wellcome Open Research
- NIH RECOVER large-scale effort and reporting on diagnostic difficulty. (News summary and analysis). The Guardian
- Time/BMJ cohort follow-up on symptom resolution within one year (Israeli cohort). TIME